ArticleEuropean journal of medical research2024
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer.
Zhu Wen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it